The Novo Nordisk Foundation committed up to DKK 5.5 billion (~€736 million) to the BioInnovation Institute (BII) for 2026–2035 to expand startup support, geographic reach and scale the number of startups the incubator backs annually. The long-term funding aims to double BII’s annual startup cohort and deepen European commercialization pathways for science-based ventures. The foundation framed the investment as a strategic push to bridge Europe’s gap between research excellence and company creation, citing BII’s prior track record of creating over 130 companies that attracted more than DKK 7 billion in external funding. BII said the funds will be used to increase startup volume from 20 to 40 per year, expand partnerships across Europe, and attract industry and investor interest to Danish and regional innovation. The commitment signals larger philanthropic capital flowing into translational infrastructure in Europe and is likely to influence early-stage funding, deal flow and spinout formation across life-science clusters.